Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAA vs HAD vs DA regimens for newly treated acute myeloid leukemia
ChiCTR-TRC-06000054Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2006
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of homoharringtonine, aclarubicin, cytarabine and daunorubicin in acute myeloid leukemia (AML) (3 arms), sponsored by Ruijin Hospital. Primary endpoints: 5-year disease-free survival, 5-year relapse-free survival and 1 more. Started Dec 2006; status: completed.
02
Drugs
homoharringtonineaclarubicincytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-06000054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-06000054.